Titre du document / Document title

Impact of adjuvant mitotane on the clinical course of patients with adrenocortical cancer

Auteur(s) / Author(s)

VASSILOPOULOU-SELLIN R. ⁽¹⁾ ; GUINEE V. F. ; KLEIN M. J. ⁽¹⁾ ; TAYLOR S. H. ; HESS K. R. ; SCHULTZ P. N. ⁽¹⁾ ; SAMAAN N. A. ⁽¹⁾ ;

Affiliation(s) du ou des auteurs / Author(s) Affiliation(s)

⁽¹⁾ Univ. Texas M.D. Anderson cancer cent., dep. medical specialties, sect. endocrinology, Houston TX 77030, ETATS-UNIS

Résumé / Abstract

Background. Adrenocortical carcinoma is a rare and aggressive disease with a poor prognosis. Adjuvant mitotane administration has been suggested as a strategy that might improve the outcome of patients with localized disease. Methods. The authors analyzed the clinical outcome of patients with localized or regional adrenocortical cancer. The study included 19 patients who were registered at M. D. Anderson Cancer Center during a 3-year period and who had localized or regional disease at the time of surgery. Of these, eight patients received mitotane postoperatively and continued the drug until their last contact or recurrence (Groug A, adjuvant); five patients began talking mitotane after surgery but discontined it after 2-12 months for reasons unrelated to the disease (Group P, postoperative); and six patients did not receive mitotane (Group N, no mitotane)

Revue / Journal Title

Cancer   ISSN 0008-543X   CODEN CANCAR 

Source / Source

1993, vol. 71, n^o10, pp. 3119-3123 (19 ref.)

Langue / Language

Anglais

Editeur / Publisher

Wiley-Liss, New York, NY, ETATS-UNIS  (1948) (Revue)

Mots-clés anglais / English Keywords

Carcinoma ; Human ; Adrenal cortex ; Prognosis ; Antineoplastic agent ; Postoperative ; Chemotherapy ; Adjuvant treatment ; Malignant tumor ; Adrenal cortex diseases ; Endocrinopathy ;

Mots-clés français / French Keywords

Epithélioma ; Mitotane ; Homme ; Corticosurrénale ; Pronostic ; Anticancéreux ; Postopératoire ; Chimiothérapie ; Traitement adjuvant ; Tumeur maligne ; Corticosurrénale pathologie ; Endocrinopathie ;

Mots-clés espagnols / Spanish Keywords

Epitelioma ; Hombre ; Corticosuprarrenal ; Pronóstico ; Anticanceroso ; Postoperatorio ; Quimioterapia ; Tratamiento adyuvante ; Tumor maligno ; Corticosuprarrenal patología ; Endocrinopatía ;

Localisation / Location

INIST-CNRS, Cote INIST : 2701, 35400003375020.0360